Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 7/20 | 0.46 |
| ▸ | EGFR | P00533 | 5/20 | 0.40 |
| ▸ | BTK | Q06187 | 6/20 | 0.39 |
| ▸ | LCK | P06239 | 2/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | CDK14 | O94921 | 2/20 | 0.37 |
| ▸ | CCNY | Q8ND76 | 2/20 | 0.37 |
| ▸ | CCNK | O75909 | 1/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2618873 | 0.88 | JAK3 (0.48) | JAK3EGFRBTKLCKCDK4 | |
| SCHEMBL17928309 | 0.88 | JAK3 (0.48) | JAK3EGFRBTKLCKCDK4 | |
| SCHEMBL410261 | 0.88 | JAK3 (0.48) | JAK3EGFRBTKLCKCDK4 | |
| SCHEMBL21345775 | 0.87 | GAA (0.37) | JAK3EGFRBTKCDK4CDK7 | |
| SCHEMBL26469442 | 0.85 | JAK3 (0.45) | JAK3EGFRBTKLCKCDK4 | |
| SCHEMBL20892752 | 0.84 | JAK3 (0.41) | JAK3EGFRBTKLCKCDK4 | |
| SCHEMBL20892949 | 0.84 | JAK3 (0.41) | JAK3EGFRBTKLCKCDK4 | |
| SCHEMBL18909691 | 0.79 | JAK3 (0.46) | JAK3EGFRBTKLCK | |
| SCHEMBL18431345 | 0.79 | JAK3 (0.46) | JAK3EGFRBTKLCK | |
| SCHEMBL18331788 | 0.79 | JAK3 (0.46) | JAK3EGFRBTKLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200108072-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200108072-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | JAK3 72/4885EGFR 836/4885BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.